Contineum Therapeutics’ (CTNM) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research report released on Thursday,Benzinga reports. They currently have a $31.00 target price on the stock.

Other equities analysts have also issued research reports about the company. Baird R W raised Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Robert W. Baird assumed coverage on shares of Contineum Therapeutics in a report on Tuesday, October 22nd. They issued an “outperform” rating and a $32.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $29.25.

Contineum Therapeutics Trading Down 2.9 %

Shares of CTNM opened at $13.37 on Thursday. The firm has a 50-day simple moving average of $15.08 and a two-hundred day simple moving average of $17.39. Contineum Therapeutics has a 1-year low of $12.33 and a 1-year high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Wednesday, November 6th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01. As a group, research analysts expect that Contineum Therapeutics will post -2.01 EPS for the current fiscal year.

Institutional Trading of Contineum Therapeutics

A number of large investors have recently made changes to their positions in the company. Franklin Resources Inc. grew its holdings in Contineum Therapeutics by 130.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,447,550 shares of the company’s stock worth $27,706,000 after acquiring an additional 820,542 shares in the last quarter. Barclays PLC raised its holdings in shares of Contineum Therapeutics by 248.6% in the 3rd quarter. Barclays PLC now owns 8,308 shares of the company’s stock valued at $158,000 after purchasing an additional 5,925 shares in the last quarter. State Street Corp lifted its position in shares of Contineum Therapeutics by 23.7% during the 3rd quarter. State Street Corp now owns 113,566 shares of the company’s stock worth $2,174,000 after purchasing an additional 21,760 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Contineum Therapeutics by 1,248.6% during the third quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock worth $129,000 after purchasing an additional 6,243 shares in the last quarter. Finally, FMR LLC increased its holdings in Contineum Therapeutics by 115.4% in the third quarter. FMR LLC now owns 696,927 shares of the company’s stock valued at $13,339,000 after buying an additional 373,327 shares during the last quarter.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).